METABOLISM AND DISPOSITION OF CALCIMIMETIC AGENT CINACALCET HCL IN HUMANS AND ANIMAL MODELS
Authors:
Open Access
- 1 December 2004
- journal article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 32 (12) , 1491-1500
Abstract
The metabolism and disposition of calcimimetic agent cinacalcet HCl was examined after a single oral administration to mice, rats, monkeys, and human volunteers. In all species examined, cinacalcet was well absorbed, with greater than 74% oral bioavailability of cinacalcet-derived radioactivity in monkeys and humans. In rats, cinacalcet-derived radioactivity was widely distributed into most tissues, with no marked gender-related differences. In all animal models examined, radioactivity was excreted rapidly via both hepatobiliary and urinary routes. In humans, radioactivity was cleared primarily via the urinary route (80%), with 17% excreted in the feces. Cinacalcet was not detected in the urine in humans. The primary routes of metabolism of cinacalcet were N-dealkylation leading to carboxylic acid derivatives (excreted in urine as glycine conjugates) and oxidation of naphthalene ring to form dihydrodiols (excreted in urine and bile as glucuronide conjugates). The plasma radioactivity in both animals and humans was primarily composed of carboxylic acid metabolites and dihydrodiol glucuronides, with <1% circulating radioactivity accounting for the unchanged cinacalcet. Overall, the circulating and excreted metabolite profile of cinacalcet in humans was qualitatively similar to that observed in preclinical animal models.Keywords
This publication has 14 references indexed in Scilit:
- The Calcimimetic AMG 073 as a Potential Treatment for Secondary Hyperparathyroidism of End-Stage Renal DiseaseJournal of the American Society of Nephrology, 2003
- Calcimimetics: therapeutic potential in hyperparathyroidismCurrent Opinion in Pharmacology, 2002
- Drug Metabolites in Safety TestingToxicology and Applied Pharmacology, 2002
- The Species-Dependent Metabolism of Efavirenz Produces a Nephrotoxic Glutathione Conjugate in RatsToxicology and Applied Pharmacology, 2000
- Preclinical review of cerivastatin sodium—a step forward in HMG-CoA reductase inhibitionAtherosclerosis, 1998
- Calcimimetics with potent and selective activity on the parathyroid calcium receptorProceedings of the National Academy of Sciences, 1998
- Metabolism of the calcium antagonist, mibefradil (POSICORTM, Ro 40-5967). Part III. Comparative pharmacokinetics of mibefradil and its major metabolites in rat, marmoset, cynomolgus monkey and manXenobiotica, 1997
- An Introduction to Drug Disposition: The Basic Principles of Absorption, Distribution, Metabolism, and ExcretionToxicologic Pathology, 1995
- Goals, Design, Timing, and Future Opportunities for Nonclinical Drug Metabolism StudiesToxicologic Pathology, 1995
- Are we doing too many animal biodisposition investigations before Phase I studies in man?European Journal of Drug Metabolism and Pharmacokinetics, 1994